Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the provided transcript. Current finance costs have increased due to higher working capital borrowings and GST interest charges. Net debt-to-equity ratio improved to 0.30x as of March 31, 2024, from 0.34x in the previous year, despite investments in CAPEX. Management discussed ongoing investments in Mahad and Baroda plants but did not indicate raising new debt or equity for these. Interest cost guidance for the next financial year is INR 17-18 crore, indicating existing debt servicing but no new major debt raising. Overall, n

Any current/future capex/capital investment/strategic investment?

Oriental Aromatics has ongoing investments in two major CAPEX projects at Mahad and Baroda, which are at advanced stages of commercial production with trial runs currently underway. The new capacities are expected to contribute to revenue growth starting effectively from Q3 FY '24-'25 or Q1 FY '25-'26. No alarming new CAPEX is expected in the camphor business side, though existing supply-demand gaps persist. The asset turnover ratios for the new CAPEX are approximately 1.2 for Mahad (Greenfield) and around 1.5 for Brownfield expansions. The company is cautiously optimistic about utiliz

Future growth expectations in sales/revenue/volumes?

The company is cautiously optimistic about growth in the Aroma Chemicals and Fragrance & Flavor divisions driven by steady demand revival and reduced raw material prices. New capacities in Mahad and Baroda are at advanced trial stages; commercial contributions expected from Q3 FY '24-'25 and fully from Q1 FY '25-'26. Expected revenue from new capacities: asset turnover around 1.2 to 1.5 times CAPEX; projections suggest ~Rs. 100-120 crores top line from new units in FY '25. Capacity utilization for new plants targeted at 60-80% in the first year. Export contribution increased from 30% to 44%, l

Future growth expectations in earnings/operating earnings/profits/EPS?

The management is cautiously optimistic about demand revival and expects steady growth in the Aroma Chemicals and Fragrance & Flavor divisions in FY '25. They project EBITDA margins improvement, targeting between 10% to 12% in the near future, likely by FY '26. New capacities (e.g., Mahad and Baroda plants) are expected to contribute meaningfully to revenues from FY '25, with anticipated utilization between 60% to 80%. The company aims for profitable growth across all segments despite challenges like camphor powder and terpene chemicals overcapacity. Interest costs are expected around

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in quantified terms. However, management expressed cautious optimism about increasing demand and growth in their Specialty Ingredients and Fragrance and Flavor divisions. Trial production is ongoing in new capacities at Mahad and Baroda, with commercial contributions expected within 6 to 9 months, implying an expanding order inflow for these new plants. Customer feedback indicates healthy demand with expected first-year utilization of 60% to 80% for the newly commissioned plants. The company is

Oriental Aromat.Q4 FY24Chemicals & Petrochemicals

Oriental Aromat. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹532P/E: 337.6Market Cap: ₹1.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company is cautiously optimistic about growth in the Aroma Chemicals and Fragrance & Flavor divisions driven by steady demand revival and reduced raw material prices.
New capacities in Mahad and Baroda are at advanced trial stages; commercial contributions expected from Q3 FY '24-'25 and fully from Q1 FY '25-'26.
Expected revenue from new capacities: asset turnover around 1.2 to 1.5 times CAPEX; projections suggest ~Rs. 100-120 crores top line from new units in FY '25.
Capacity utilization for new plants targeted at 60-80% in the first year.
Export contribution increased from 30% to 44%, led by Specialty Ingredients and Fragrance & Flavor divisions.
Continued focus on profitable growth, with a balanced product mix across three verticals (~33% each).
Targeting EBITDA margins of 10-12% in FY '25 or FY '26 as business stabilizes and demand improves.

Margin guidance

Category 3

The management is cautiously optimistic about demand revival and expects steady growth in the Aroma Chemicals and Fragrance & Flavor divisions in FY '25.
They project EBITDA margins improvement, targeting between 10% to 12% in the near future, likely by FY '26.
New capacities (e.g., Mahad and Baroda plants) are expected to contribute meaningfully to revenues from FY '25, with anticipated utilization between 60% to 80%.
The company aims for profitable growth across all segments despite challenges like camphor powder and terpene chemicals overcapacity.
Interest costs are expected around INR 17-18 crore, with depreciation increasing due to new CAPEX, reflecting planned capacity expansions.
Cash flow improvements are noted with operating cash flow at INR 142 crore in FY '24, aiding financial stability for growth.
Overall, management anticipates volume growth, improved profitability, and EPS recovery aligned with business stability and expansion efforts.

See what Oriental Aromat. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any new fundraising through debt or equity in the provided transcript.
Current finance costs have increased due to higher working capital borrowings and GST interest charges.
Net debt-to-equity ratio improved to 0.30x as of March 31, 2024, from 0.34x in the previous year, despite investments in CAPEX.
Management discussed ongoing investments in Mahad and Baroda plants but did not indicate raising new debt or equity for these.
Interest cost guidance for the next financial year is INR 17-18 crore, indicating existing debt servicing but no new major debt raising.
Overall, no clear plans shared regarding fresh debt or equity fundraising in near term.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in quantified terms.
However, management expressed cautious optimism about increasing demand and growth in their Specialty Ingredients and Fragrance and Flavor divisions.
Trial production is ongoing in new capacities at Mahad and Baroda, with commercial contributions expected within 6 to 9 months, implying an expanding order inflow for these new plants.
Customer feedback indicates healthy demand with expected first-year utilization of 60% to 80% for the newly commissioned plants.
The company is focused on profitable growth and expects steady demand recovery across divisions despite challenges in the camphor and terpene chemical segments.
No exact figures or timelines on the complete order book or pending orders were disclosed during the call.

See what Oriental Aromat. management said on order book — free account, 30 seconds.

Capex plans

Oriental Aromatics has ongoing investments in two major CAPEX projects at Mahad and Baroda, which are at advanced stages of commercial production with trial runs currently underway.
The new capacities are expected to contribute to revenue growth starting effectively from Q3 FY '24-'25 or Q1 FY '25-'26.
No alarming new CAPEX is expected in the camphor business side, though existing supply-demand gaps persist.
The asset turnover ratios for the new CAPEX are approximately 1.2 for Mahad (Greenfield) and around 1.5 for Brownfield expansions.
The company is cautiously optimistic about utilization and breakeven timelines, aiming for 60%-80% utilization in the first year of operations.
Focus remains on profitable growth with strategic capacity utilization without immediate plans for large-scale new investments beyond current projects.

Track Oriental Aromat. — get its next earnings analysis in your feed

How does Oriental Aromat. rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisOriental Aromat.

Rev 3Mar 3

See where Oriental Aromat. sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Oriental Aromat. rank in Chemicals & Petrochemicals?

Compare Oriental Aromat. against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Oriental Aromat.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Oriental Aromat. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Oriental Aromat. rank in Chemicals & Petrochemicals?

Continue your research

What Oriental Aromat.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season